

CURRICULUM VITAE

ALEXANDER BYSTRITSKY, M.D., Ph.D.

PERSONAL HISTORY

UCLA Neuropsychiatric Institute and Hospital
300 UCLA Medical Plaza, Suite 2335, Los Angeles, CA 90024
Business Tel.: (310) 206-5177 / (310) 206-5133

15002 Sunstone Place, Sherman Oaks, CA 91403
Home Tel.: 818-990-3849

Born: January 18, 1954; Leningrad, U.S.S.R.
Citizen of U.S.A.

EDUCATION

1971-1977

Pavlov Medical University, St. Petersburg, Russia
M.D.

1977-1979

Pavlov Medical University, St. Petersburg, Russia
Ph.D. (equivalent) – Psychopharmacology

1981-1985

New York University-Bellevue Medical Center, New York, NY
Resident in Psychiatry (Chief Resident of Anxiety Disorders
Program as PGY-4)

1985-1987

University of California, Los Angeles, Los Angeles, CA
Robert Wood Johnson Clinical Scholar

2003-2006

Confirmed as the Ph.D. degrees in Clinical Psychiatry and
Psychopharmacology by the S.P. Pavlov Medical University

LICENSURE

State of California # A04132
State of New York # 159550

BOARD CERTIFICATION

American Board of Psychiatry and Neurology # 30209

PROFESSIONAL EXPERIENCE

Present position

Professor of Psychiatry and Biobehavioral Sciences,
UCLA School of Medicine
Director, Anxiety Disorder Program
UCLA Neuropsychiatric Institute & Hospital, Los Angeles, CA

CEO, Brainsonix Corp., Sherman Oaks, California

- 1977-1979 Ph.D. Candidate
Pavlov Medical University, St. Petersburg, Russia
Institute of Experimental Medicine
- 1980-1981 Assistant Research Scientist
New York University Medical Center
- 1981-1985 Resident in Psychiatry (Chief Resident of Anxiety Disorders
Program as PGY-4)
New York University-Bellevue Medical Center, New York, NY
- 1985-1987 Robert Wood Johnson Clinical Scholar
University of California, Los Angeles, Los Angeles, CA
- 1987- Director of Anxiety Disorders Program
Neuropsychiatric Institute and Hospital
University of California, Los Angeles, Los Angeles, CA
- 1987- Director of Outpatient Psychopharmacology
Neuropsychiatric Institute and Hospital
University of California, Los Angeles, Los Angeles, CA
- 1990- Attending Physician, Neuropsychiatric Hospital
University of California, Los Angeles, Los Angeles, CA
- 1991- Director, Partial Hospitalization Program for Treatment Resistant
Anxiety Disorder, Neuropsychiatric Hospital
University of California, Los Angeles, Los Angeles, CA
- 1997- 2000 Associate Director, Clinical Psychopharmacology Research Center
Neuropsychiatric Institute and Hospital
University of California, Los Angeles, Los Angeles, CA
- 2007- Visiting Professor at Full Professor Level Neuroscience and
Radiology, Brigham and Women's Hospital, Harvard School of
Medicine, Boston, Massachusetts

PROFESSIONAL ACTIVITIES

Memberships

American Psychiatric Association
Southern California Psychiatric Society
Anxiety Disorders Association of America
Russian-American Medical Society
Western Coast College of Biological Psychiatry
American Medical Association
California Alliance for Mentally Ill
OCD Foundation
College Internationale NeuroPsychopharmacology
American Society of Pharmacology and Therapeutics
American Society of Clinical Psychopharmacology
Bellevue Psychiatric Society

Committee/Community/Teaching Service

1986- Volunteer Psychiatric Consultant for The Russian-American Society and Jewish Community Services of Los Angeles
1987- Member, UCLA Pharmacy and Therapeutics Committee
1989- PGY 2-4 Residents' Supervisor
1989- Lecturer for UCLA Clinical Pharmacology Course
1994- Expert Treatment Panel of Anxiety Disorders Association of America
1995- Chair, Committee on Clinical Trials, American Society for Clinical Psychopharmacology
1995-1998 Chair, Committee on International Affairs, Southern California Psychiatric Society
1997- Member, Scientific Advisory Board, OCD Foundation, Western Region
1997- Treatment and Assessment Consultant for Anxiety Disorders Rand Corporation, Santa Monica
1997- Pacific Institute for Medical Research, Consultant

Editorial Service

1987- Reviewer for Archives of General Psychiatry
1989- Reviewer for Journal of Anxiety Disorders
1990- Reviewer for American Journal of Psychiatry
1993- Reviewer for Journal of Nervous Mental Disorder
1993- Reviewer for Depression and Anxiety
1994- Reviewer for Journal of Geriatric Psychiatry

HONORS AND SPECIAL AWARDS

1975	Best Student Research Paper Leningrad.
1976	Gold Medal for Best Student Research Paper in U.S.S.R.
1977	Maria Petrova Award - The Most Outstanding Young Scientist Paper in the fields of Psychiatry and Neurology in the U.S.S.R.
1985	Robert Wood Johnson Clinical Scholar
1994	Bristol Myers Distinguished Faculty
1994	Janssen Clinical Scholar
1994	Special Recognition Service Award, SCPA
1995-	Who's Who in the United States, #16531
1995-	Best Doctors in America, Western Region
1996	Physician Recognition Award, California Medical Association
1996	Best Doctors in Los Angeles, LA Magazine Listing
1997	Fellow, American Psychiatric Association
1998	Best Doctors in America (General Listing)
1999	Who is Who in the World
2000	America's Top Doctors (Connolly Guide)
2001	Distinguished Fellow of APA
2005	Man of the Year Listings
2005	OC Foundation Research Award
2009	NARSAD Distinguished Investigator Award

RESEARCH GRANTS RECEIVED**Current Grant Support**

Co-Principal Investigator-UCLA Site, Improving Care for Anxiety Patients in Primary Care (20% effort)

NIMH 2U01MH058915-05A2 (PI-Michelle Craske) \$2,667,837
2005-2010

The goal of this project is to implement an intervention to identify and treat panic disorder in the primary care setting as well as study its clinical & cost effectiveness.

Principal Investigator, Comparative trial of sertraline and sertraline/aripiprazole combination in Obsessive Compulsive Disorder (20% effort)

OCD Foundation \$49,000
2005-2007

The goal is to explore whether the combination of neuroleptic and an SSRI has faster and more robust onset of action.

Principal Investigator, Saban Family Foundation Exploration of New Treatments of Anxiety (20% effort)

Saban Family Foundation \$180,000
2004-2007

The goal of this project is to create groundwork for the discovery and testing of new treatments of anxiety.

Principal Investigator, fMRI-guided Slow rTMS in the Treatment of Generalized Anxiety Disorder (20% effort)

Harvey Family Foundation \$123,000
2004-2007

The goal of this project is to create groundwork for the testing of the new treatments of anxiety using rTMS under guidance of fMRI.

Recently completed studies

Principal Investigator-UCLA site, St. Johns Wart vs. Placebo in OCD (20% effort)

NCCAM Grant R21 AT00391-01A1 \$127,000
2003-2005

The goal of this project is to evaluate the efficacy of St. Johns Wart in patients with OCD.

LECTURES AND PRESENTATIONS

1. Levine SH, Anderson D, **Bystritsky A**. The treatment and evaluation of depression in patients infected with HIV, Abstract 54, presented at APA, paper session (peer reviewed), 87-88, New York, 1990.
2. **Bystritsky A**, Fogelson DL, Doctor R. Differences between patients with different orientation, Abstract 98, Presented at APA, paper session (peer reviewed), 103, New York, 1990.
3. O'Keefe Z, **Bystritsky A**, Shapiro D. Ambulatory monitoring in panic patients, American Psychological Association Meeting, San Diego, 1992.
4. Gorbis E, Munford PR, **Bystritsky A**. Abuse as a factor in expression and treatment of OCD, Poster, San Diego, 1994.
5. Martin K, Wolson R, Munford PR, **Bystritsky A**, Baxter LR. PHP for OCD, Poster, Association of Psychiatric Health Systems, San Diego, 1994.
6. Waikar SV, **Bystritsky A**, Craske MG, Murphy KJ. Etiological beliefs and treatment-seeking behavior in anxiety disordered patients, Poster, ADAA Meeting, Santa Monica, 1994.
7. **Bystritsky A**, Waikar SV. Preliminary report on the new psychometric instrument for panic and anxiety, Poster, ADAA Meeting, Santa Monica, 1994.
8. Chen E, Maidenberg E, Craske MG, **Bystritsky A**. Attentional bias in panic disorder and social phobia, Poster, AABT, San Diego, 1994.

9. Ackerman DL, Greenland S, **Bystritsky A**, Katz R. Clomipramine and obsessive compulsive disorder: Evaluating response predictors, NCDEU Meeting, Orlando, FL, 1995.
10. Cohen S, Craske MG, Maidenberg E, **Bystritsky A**. Social learning of maladaptive cognitions in panic disorder, WPA Annual Meeting, 1995.
11. **Bystritsky A**, Maidenberg E, Craske MG, Schapiro D. Autonomic reactivity of panic patients during CO₂ inhalation procedure, AABT Meeting, 1995.
12. **Bystritsky A**, Maidenberg E, Craske MG, Vapnik T, Schapiro D. Autonomic reactivity of panic patients during CO₂ inhalation procedure, Abstract and Poster presentation, Annual Meeting, American Psychiatric Association, New York, 1996.
13. **Bystritsky A**, Maidenberg E, Craske MG, Vapnik T, Schapiro D. Autonomic reactivity of panic patients during psychophysiological assessment. Abstract and Oral presentation, Symposium on Psychophysiology of Panic Disorder, Abstract, Annual Meeting, American Psychiatric Association, San Diego, 1997.
14. **Bystritsky A**, Vapnik T, Leuchter A. Computerized EEG Abnormalities in non-medicated panic patients, Abstract and Poster, presented at NCDEU Meeting Boca Raton, FL, 1997.
15. **Bystritsky A**, Saxena S, Maidment K, Vapnik T, Tarlow G, Rosen R. Quality of life changes in treatment-resistant OCD, Abstract and Poster presentation, ACNP Meeting, Waikoloa Village, HI, 1997.
16. **Bystritsky A**, Rosen R, Suri R, Vapnik T. Pilot open-label study of nefazodone in panic disorder, Abstract and Poster presentation, ACNP Meeting, Waikoloa Village, HI, 1997.
17. **Bystritsky A**, Craske MG, Maidenberg E, Vapnik T, Schapiro D. Breathing configuration of panic patients during a CO₂ inhalation procedure, Abstract and Poster presented at NCDEU Meeting, Boca Raton, FL, 1998.
18. Ackerman DL, **Bystritsky A**. Utilization and cost comparison of inpatient antidepressant drugs, The 15th International Conference on Pharmacoepidemiology, 26-29, 1999.
19. **Bystritsky A**, Liberman RP, Hwang S, Saxena S, Maidment K, Vapnik T. OCD versus schizophrenia pre-post treatment assessment, Poster presented at the Annual Meeting of American Psychiatric Association, Washington DC, 1999.
20. **Bystritsky A**, Maidment K, Vapnik T, Tarlow G. Management clients with treatment resistant OCD, Abstract and Symposium presented at the Anxiety Disorders Association of America Annual Meeting, San Diego, 1999.
21. **Bystritsky A**, Craske MG, Maidenberg E, Vapnik T, Schapiro D. Cardiovascular and respiratory changes in panic patients in the light of current biological theories of Panic, Abstract and Oral

- Presentation, presented at the Anxiety Disorders Association of America Annual Meeting, San Diego, 1999.
22. **Bystritsky A**, Craske MG, Sandbrand DC. Preliminary analysis of the neuropsychological effects of visual imagery in panic disorder patients: An fMRI study, Abstract and Oral Presentation, presented at the Anxiety Disorders Association of America Annual Meeting, San Diego, 1999.
 23. **Bystritsky A**, Bystritsky M. Russian language assessment of mental illness, Symposium Presentation and Abstract, Annual Meeting of American Psychiatric Association, Washington DC, 1999.
 24. **Bystritsky A**, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of SRI response in refractory OCD using adjunct olanzapine: A placebo-controlled study, Abstract and Poster, ACNP, San Juan, 2000.
 25. **Bystritsky A**, Pontillo D, Powers M, Sabb FW, Craske MG, Bookheimer SY. FMRI changes in panic patients during imagery exposure, Abstract and Poster, ACNP, San Juan, 2000.
 26. **Bystritsky A**, Pontillo D, Powers M, Sabb FW, Craske MG, Bookheimer SY. FMRI changes in panic patients during imagery exposure. Presentation and Abstract, Psychiatric Research Society, Park City, UT, 2001.
 27. Roy-Byrne P, Russo J, Pollack M, Steward R, **Bystritsky A**, Bell J, Rosenbaum J, Corrigan MH, Stolk J, Rush AJ, Ballenger J. Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder, Abstract and Poster, ACNP, San Juan, 2002.
 28. Roy-Byrne PP, Sherbourne CD, Craske MG, Stein MB, Katon WJ, Sullivan G, Means A, **Bystritsky A**. CBT and Medication for Primary Care Panic Disorder: Sustained Superiority to Usual Care, Abstract and Poster, ACNP, San Juan, 2002.
 29. **Bystritsky, A**. Current Treatments of OCD. Abstract and Poster Proceeding of the Bekhterev Institute, St. Petersburg, Russia, July 2002.
 30. **Bystritsky, A**. Integrated Treatment of OCD, Kongress Zwangserkrankungen, Prien, Germany, November 2003.
 31. **Bystritsky, A**. OCD Management in Partial Program, Abstract and Poster, 6th IOCDC Meeting, Lanzarote, Spain, November 2003.
 32. **Bystritsky, A**. Anxiety as Residual Symptoms of Depression, APA Symposia and Abstract., APA Annual Meeting, New York, May 2004.

33. Feusner, JD, **Bystritsky A.** Effect Size of UCLA 4-D Anxiety-Depression Scale as Compared to Other Anxiety Scales, Abstract and Poster, Anxiety Disorder Association Of America, Abstract and Poster, Florida, March 2004.
34. Feusner JD, **Bystritsky A.** UCLA Anxiety Disorders Clinic: training psychiatric residents in cognitive-behavioral therapy and pharmacotherapy in a specialty population. Presented at the Anxiety Disorders Association of America Annual Conference, Seattle, 2005.
35. **Bystritsky A**, Natoli J, Klap R, Wells KB, Young A. Prevalence of Psychiatric Comorbidities Among Subjects with Clinical and Subthreshold Panic Disorder. Abstract and Poster, 1-67. New Clinical Drug Evaluation Unit Program, Boca Raton, FL, May 2005.
36. **Bystritsky A**, Natoli J, Klap R, Wells KB, Young A. Prevalence of Psychiatric Comorbidities Among Subjects with Clinical and Subthreshold Panic Disorder. Abstract and Poster, International Conference: Bridging Eastern and Western Psychiatry, Moscow, June 2005.
37. Prenoveau JM, Craske M, Roy-Byrne PP, Sherbourne CD, Stein MB, **Bystritsky A.** Predictors of Willingness to Consider Medication and Psychological Treatment for Panic Disorder in Primary Care. Abstract and Poster, Association of Behavior and Cognitive Therapies. Washington D.C., November, 2005.
38. **Bystritsky A**, Kerwin L, Vapnik T. A Pilot Controlled Trial of Bupropion vs. Es-Citalopram in GAD, Abstract and Poster, Psychiatric Congress, Las Vegas, November, 2005.
39. **Bystritsky A**, Kerwin L, Vapnik T. A Pilot Controlled Trial of Bupropion vs. Es-Citalopram in GAD, Abstract and Poster, ACNP, Hawaii, December, 2005.
40. **Bystritsky A**, Kerwin, L, Vapnik T, Feusner JD. A pilot controlled trial of bupropion XL vs. escitalopram in generalized anxiety disorder. Poster, Anxiety Disorders Association of America Annual Conference, Miami, 2006.
41. Feusner JD, **Bystritsky A**, Bookheimer, S. Impaired processing of faces with emotional expressions in body dysmorphic disorder: preliminary results. Poster, Anxiety Disorders Association of America Conference, Miami, 2006.
42. Rose RD, Craske MG, Stein MB, **Bystritsky A**, Sherbourne CD, Roy-Byrne PP. Unmet Need and Perceived Barriers to Care among Primary Care Patients with Panic Disorder. Paper presented at the Anxiety Disorders Association 26th Annual Meeting, Miami, FL, March, 2006.
43. Feusner JD, **Bystritsky A**, Townsend J, Bookheimer S. Regional brain activation in body dysmorphic disorder with visual processing of others' faces. Poster, Future Leaders of Psychiatry meeting, Miami, 2006.

44. Feusner JD, **Bystritsky A**, Townsend J, Bookheimer S. Visual information processing in body dysmorphic disorder: preliminary results. Poster, Organization for Human Brain Mapping Conference, Florence, Italy, 2006.
45. **Bystritsky A**, Kerwin L, Vapnik T. A Pilot Controlled Trial of Bupropion vs. Es-Citalopram in GAD, Abstract and Poster, APA, Toronto, May, 2006.
46. **Bystritsky A**, Koback K., Vapnik T. A Double Blind, Placebo Controlled Trial of St. John's Wart in OCD, Paper and Abstract, Complimentary and Alternative Treatments Conference, Edmonton-Alberta, Canada, May 2006.
47. **Bystritsky A**, Kerwin L, Vapnik T. A Pilot Controlled Trial of Bupropion vs. Es-Citalopram in GAD, Abstract and Poster, NCDEU, Boca Raton, Florida, June, 2006.
48. **Bystritsky A**, Kerwin L, Vapnik T. A Pilot Controlled Trial of Bupropion vs. Es-Citalopram in GAD, Abstract and Poster, Institute of Psychiatry, New York, October, 2006.
49. Feusner JD, **Bystritsky A**, Townsend J, Bookheimer S. Visual information processing of faces in body dysmorphic disorder. Abstract and Poster, The American College of Neuropsychopharmacology Annual Meeting, 2006.
50. Rose RD, Craske MG, Stein MB, **Bystritsky A**, Sherbourne CD, Roy-Byrne PP, Edlund MJ, Sullivan G. Training Primary Care Staff to Deliver a Computer-Assisted CBT Treatment Program for Anxiety Disorders. Paper presented at the annual meeting of the Association of Behavioral and Cognitive Therapies, Chicago, IL, November, 2006.
51. Feusner JD, Townsend J, **Bystritsky A**, Bookheimer S. Correlation between symptoms of body dysmorphic disorder and brain activation patterns with visual processing: preliminary results. Poster, Organization for Human Brain Mapping Annual Conference, 2007.
52. Powers MB, Smits J, Whitley D, **Bystritsky A**, Telch M. Attribution processes concerning medication taking following exposure-based treatment and their subsequent effects on return of fear at follow-up. Abstract and Presentation, World Congress of Behavioural and Cognitive Therapies, Barcelona, Spain, July, 2007.
53. Powers MB, Smits JA, Whitley D, **Bystritsky A**, Telch M. Attributional processes concerning medication taking and their subsequent effects on fear reduction during exposure-based treatment: A work in progress. Poster and Abstract, the Association for the Advancement of Behavior Therapy, New Orleans, Louisiana, 2007.

PUBLICATION/BILIOGRAPHY**RESEARCH PAPERS (peer reviewed)**

1. Rabey JM, Passeltiner P, **Bystritsky A**, Engel J, Goldstein M. The regulation of striatal dopa synthesis by alpha-2 adrenoreceptors, Brain Res, 230:422-426, 1981.
2. Goldstein M, Engel J, **Bystritsky A**, Mino S. Therapeutic potentials of centrally acting dopamine and alpha-2 receptor agonists, J Neural Transm, 18:257-265, 1983.
3. Fogelson DL, **Bystritsky A**, Sussman N. Interrelationships between major depression and the anxiety disorders: Clinical relevance, Psychiatric Annals, 18:31 158-167, 1988.
4. Fogelson D, **Bystritsky A**, Katz R, DeVeugh-Geiss J, Landau P. Obsessive-compulsive disorder treatment response to clomipramine hydrochloride and influence of affective disturbance, Biol Psychiatry, (Supplement) 25:184a-193a, 1989.
5. Pasnau RO, **Bystritsky A**. Overview of anxiety disorders. Bull Menninger Clin, 54(2):157-169, 1990.
6. Pasnau RO, **Bystritsky A**. The importance of treating anxiety in elderly ill patients, Psychiatric Medicine, 8(3):163-173, 1990.
7. **Bystritsky A**, Ware JE, Linn LS. Development of a multidimensional scale of anxiety, Journal of Anxiety Disorders, 4:99-115, 1990.
8. Levine S, Anderson D, **Bystritsky A**, Baron D. A report of eight HIV-seropositive patients with major depression responding to fluoxetine, J Acquir Immune Defic Syndr, 3:1074-1077, 1990.
9. **Bystritsky A**, Pasnau RO. Initial reaction and response to antidepressants, Am J Psychiatry, 147:11:1575, 1990.
10. **Bystritsky A**, Ackerman DL, Pasnau RO. Low dose desipramine treatment of cocaine related panic attacks, J Nerv Ment Dis, 179:755-758, 1991.
11. **Bystritsky A**, Pasnau RO. Switching from alprazolam to buspirone, J Clin Psychopharmacol, 11:3:219-220, 1991.
12. Fogelson DL, **Bystritsky A**. Imipramine in the treatment of obsessive compulsive disorder with and without depression, Ann Clin Psychiatry, 3:3:1230-1237, 1991.
13. Levine S, **Bystritsky A**, Barron D, Jones L. Group psychotherapy for HIV-seropositive patients with major depression, Am J Psychother, XLV:2:112-116, 1991.

14. Fogelson DL, **Bystritsky A**, Pasnau RO. Bupropion in the treatment of bipolar disorders: The same old story, J Clin Psychiatry, 53:443-446, 1992.
15. Davis KL and the Tacrine Collaborative Study Group (**Bystritsky** named as member). A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease, N Engl J Med, 327(18):1253-1259, 1992.
16. **Bystritsky A**, Shapiro D. Continuous physiological and subjective reports in panic patients: A preliminary methodological report, Biol Psychiatry, 32:766-777, 1992.
17. **Bystritsky A**, Fogelson DL, Doctor R, Yager J. Symptom differences among patients in clinics with differing treatment orientations, Am J Psychother, 2:2:164-170, 1993.
18. **Bystritsky A**, Stoessel P, Yager J. Psychometric discrimination between anxiety and depression, J Nerv Ment Dis, 181:4:265-267, 1993.
19. Katz RJ, Landau PS, Lott M, **Bystritsky A**, Diamond B, Hoehn-Saric R, Rosenthal M, Schweizer E, Weise C. Serotonergic (5-HT₂) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorders: 5-HT₂, Biol Psychiatry, 34:41-44, 1993.
20. Mendels J, Johnston R, Mattes J, Riesenberg R (An Expert's Group, **Bystritsky** named as member). Efficacy and safety of b.i.d. doses of venlafaxine in a dose- response study, Psychopharmacol Bull, 29:169-174, 1993.
21. Sherbourne CD, Wells KB, Judd LL, with Panic Disorder Outcome Study Team, (An Expert's Group, **Bystritsky** named as member). Rand Publication, 1994.
22. Shear MK, Maser J, (An Expert's Group, **Bystritsky** named as member). Standardized assessment for panic disorder research, Arch Gen Psychiatry, 51:346-364, 1994.
23. Ackerman DL, Greenland S, **Bystritsky A**, Morgenstern H, Katz RJ. Predicators of treatment response in obsessive compulsive disorder: Multivariate analyses from a multicenter trial of clomipramine, J Clin Psychopharmacol, 14:4:247-254, 1994.
24. **Bystritsky A**, Waikar SV. Inert placebo versus active medication: Patient blindability in clinical pharmacological trials, J Nerv Mental Dis, 182:9:485-487, 1994.
25. Targ EF, Karasic DH, Diefenbach PN, Anderson DA, **Bystritsky A**, Fawzy FI. Structured group therapy and fluoxetine to treat depression in HIV-positive persons, Psychosomatics, 35:(2):132-137, 1994.
26. Waikar SV, **Bystritsky A**, Craske MG, Murphy KJ. Etiological beliefs and treatment seeking behavior in anxiety-disordered patients, Anxiety, 1:134-137, 1995.

27. **Bystritsky A**, Rosen RM, Murphy KJ, Bohn P, Keys SA, Vapnik T. Double-blind pilot trial of desipramine vs. fluoxetine in panic patients, J of Anxiety Disorders, 1:287-290, 1995.
28. Stoessel PW, **Bystritsky A**, Pasnau RO. Distinguishing anxiety disorders patients from medical patients in the outpatient medical setting, Family Practice, 12:448-451, 1995.
29. **Bystritsky A**, Craske M, Maidenberg E, Vapnik T, Shapiro D. Ambulatory monitoring of panic patients during regular activity: A preliminary report. Biol Psychiatry, 38:10:684-689, 1995.
30. Craske MG, Maidenberg E, **Bystritsky A**. Brief cognitive-behavioral versus nondirective therapy for panic disorder, J Behav Ther Exp Psychiatry, 26:113-120, 1995.
31. **Bystritsky A**, Waikar S, Vapnik T. The four-dimensional anxiety and depression scale, Anxiety, 2:47-50, 1995.
32. Small GW, Hamilton SH, **Bystritsky A**, Meyers BS, Nemeroff CB. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression, Int Psychogeriatr, 7:41-53, 1995.
33. **Bystritsky A**, Munford PR, Rosen RM, Martin KM, Vapnik T, Gorbis EE, Wolson RC. A preliminary study of partial hospital management of severe obsessive-compulsive disorder, Psychiatr Serv, 47:170-174, 1996.
34. Ackerman DL, Greenland S, **Bystritsky A**. Use of receiver-operator characteristic (ROC) curve analysis to evaluate predictors of response to clomipramine therapy, Psychopharmacol Bull, 32:157-165, 1996.
35. Small GW, Schneider LS, Holman SL, **Bystritsky A**. Site variability in multicenter geriatric desipramine trial, International Journal of Geriatric Psychiatry, 11:1-7, 1996.
36. Saxena S, Wang D, **Bystritsky A**, Baxter LR. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder, J Clin Psychiatry, 57:7:303-306, 1996.
37. Maidenberg E, Chen E, Craske MG, Bohn PB, **Bystritsky A**. Specificity of attention bias in panic disorder and social phobia. Journal of Anxiety Disorders, 10:529-541, 1996.
38. Small G, Birkett, M, Meyers BS, Koran LM, **Bystritsky A**, Nemeroff CB. Impact of physical illness on quality of life and antidepressant response in geriatric major depression, J Am Geriatr Soc, 44:10:1220-1225, 1996.
39. **Bystritsky A**, Strusser B. Treatment of obsessive-compulsive cutting behavior with naltrexone, J Clin Psychiatry, 57:423-424, 1996.

40. Ackerman DL, Greenland S, **Bystritsky A**, Katz RJ. Relationship between early side effects and therapeutic effects of clomopramine therapy in obsessive-compulsive disorder, J Clin Psychopharmacol, 16:324-328, 1996.
41. **Bystritsky A**, Vapnik T. Treatment of dysmorphophobia using videotape exposure, Depression and Anxiety, 5:1:39-41, 1997.
42. March JS et al., (**Bystritsky**, member of panel). The expert consensus panel report for obsessive-compulsive disorder, J Clin Psychiatry, 58(Suppl 4), 1997.
43. Schneider LS, Small GW, Hamilton SH, **Bystritsky A**, Nemeroff CB, Meyers BS. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial: Fluoxetine collaborative study group, American Journal of Geriatric Psychiatry, 5(2):97-106, 1997.
44. Ackerman DL, Greenland S, **Bystritsky A**, Small GW. Characteristics of fluoxetine vs. placebo responders in a randomized trial of geriatric depression, Psychopharmacol Bull, 33:4:707-714, 1998.
45. Roy-Byrne P, Stein M, **Bystritsky A**, Katon W. Pharmacotherapy of panic disorder: Proposed guidelines for the family physician, J Am Board of Fam Pract, 11: 282-90, 1998.
46. **Bystritsky A**, Vapnik T, Leuchter A. Computerized EEG abnormalities in non-medicated panic patients, J Nerv Ment Dis, 187:2:113-114, 1999.
47. **Bystritsky A**, Saxena S, Maidment K, Vapnik T, Tarlow G, Rosen R. Quality of life changes in treatment-resistant OCD, Psychiatr Serv, 50:3:412-413, 1999.
48. Kronig MH, Apter J, Asnis G, **Bystritsky A**, Curtis G, Ferguson J, Landbloom R, Munjack D, Riesenbergr R, Robinson D, et al. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder, J Clin Psychopharmacol, 19(2):172, 1999.
49. Foa EB, Davidson JRT, Frances A, Expert Group (**Bystritsky**, member). Expert consensus guideline for the treatment of post traumatic stress disorder, J Clin Psychiatry, Supplement 16, 1999.
50. Roy-Byrne PP, Stein MB, Russo J, Mercier E, Thomas R, McQuaid J, Katon W, Craske MG, **Bystritsky A**, Sherbourne C. Panic disorder in the primary care setting: Comorbidity, disability, service utilization and treatment, J Clin Psychiatry, 60:492-499, 1999.
51. Stein MB, Roy-Byrne PP, McQuaid JR, Laffaye C, Russo J, McCahill ME, Katon W, Craske MG, **Bystritsky A**, Sherbourne CD. Development of a brief diagnostic screen in panic disorder in primary care, Psychosom Med, 61:359-364, 1999.

52. Ackerman DL, Greenland S, **Bystritsky A**. Side effects as predictors of drug response in obsessive-compulsive disorder, J Clin Psychopharmacol, 19(5):459-65, 1999.
53. **Bystritsky A**, Rosen R, Suri R, Vapnik T. Pilot open-label study of nefazodone in panic disorder, Depress Anxiety, 10(3):137-9, 1999.
54. **Bystritsky A**, Vapnik T, Maidment K, Pynoos RS, Steinberg AM. Acute responses of anxiety disorder patients after a natural disaster, Depress Anxiety, 11(1):43-4, 2000.
55. **Bystritsky A**, Craske M, Maidenberg E, Shapiro D. Autonomic reactivity of panic patients during a CO₂ inhalation procedure, Depress Anxiety, 11(1):15-26, 2000.
56. **Bystritsky A**, Craske M, Maidenberg E, Shapiro D. Autonomic reactivity in panic patients during structured psychophysiological assessment, Depress Anxiety, 2(2):102-8, 2000.
57. Ackerman DL, Greenland S, **Bystritsky A**, Small GW. Side effects and time course of response in a placebo-controlled trial of fluoxetine for the treatment of geriatric depression, J Clin Psychopharmacol, 20(6):658-65, 2000.
58. Saxena S, Winograd A, Dunkin JJ, Maidment K, Rosen R, Vapnik T, Tarlow G, **Bystritsky A**. A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder, J Clin Psychiatry, 62(1):67-72, 2001.
59. **Bystritsky A**, Liberman RP, Hwang S, Wallace CJ, Vapnik T, Maidment K, Saxena S. Social functioning and quality of life comparisons between obsessive-compulsive and schizophrenic disorders, Depress Anxiety, 14(4):214-8, 2001.
60. **Bystritsky A**, Pontillo D, Powers M, Sabb FW, Craske MG, Bookheimer SY. Functional MRI changes during panic anticipation and imagery exposure, Neuroreport, Dec 21;12(18):3953-7, 2001.
61. Klein DF, Thase M, Endicott J, Adler L, Glick I, Kalali A, Levanter S, Mattes J, Ross P, **Bystritsky A**. Improving clinical trials: American society of clinical psychopharmacology recommendations, Arch Gen Psychiatry, Mar;59(3):272-8, 2002.
62. Craske MC, Lang AJ, Rowe M, DeCola JP, Simmons J, Mann C, Yan-Go F, **Bystritsky A**. Pre-sleep attributions about arousal during sleep: Nocturnal panic, J Abnorm Psychol, Feb;111(1):53-62, 2002.
63. Saxena S, Maidment KM, Rosen R, Vapnik T, Tarlow G, **Bystritsky A**. Obsessive-compulsive hoarding: symptom severity and response to multi-modal treatment, J Clin Psychiatry, Jan;63(1):21-7, 2002.

64. Hazlett-Stevens H, Craske MG, Roy-Byrne PP, Sherbourne CD, Stein MB, **Bystritsky A**. Predictors of willingness to consider medication and psychosocial treatment for panic disorder in primary care patients, Gen Hosp Psychiatry, Sep-Oct;24(5):316-21, 2002.
65. Craske MG, Roy-Byrne P, Stein MB, Donald-Sherbourne C, **Bystritsky A**, Katon W, Sullivan G. Treating panic disorder in primary care: a collaborative care intervention, Gen Hosp Psychiatry, May-Jun;24(3):148-55, 2002.
66. Craske MG, Lang AJ, Mystkowski JL, Zucker BG, **Bystritsky A**, Yan-Go F. Does nocturnal panic represent a more severe form of panic disorder?, J Nerv Ment Dis, Sep;190(9):611-8, 2002.
67. **Bystritsky A**. Anxiety Disorders: Alternative Treatment Strategies, Primary Psychiatry, Jul; 202:8-10, 2002.
68. Roy-Byrne PP, Sherbourne CD, Craske MG, Stein MB, Katon WJ, Sullivan G, Means A, **Bystritsky A**. Moving treatment research from clinical trials to the real world, Psychiatric Services, 54:327-332, 2003.
69. Roy-Byrne P, Russo J, Pollack M, Steward R, **Bystritsky A**, Bell J, Rosenbaum J, Corrigan MH, Stolk J, Rush AJ, Ballenger J. Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder, Psychological Medicine, 33:1-8, 2003.
70. Means-Christensen A, Sherbourne CD, Roy-Byrne P, Craske MG, **Bystritsky A**, Stein MB. The Composite International Diagnostic Interview (CIDI-Auto): problems and remedies for diagnosing panic disorder and social phobia, International Journal of Methods in Psychiatric Research, 12:167-181, 2003.
71. **Bystritsky A**. Diagnosis and Treatment of Anxiety, Focus Publications, Vol II, 3:333-343, 2004.
72. **Bystritsky A**. Current Pharmacological Treatments for Obsessive-Compulsive Disorder, Essential Psychopharmacology, 5(4):251-272, 2004.
73. Stein MB, Sherbourne CD, Craske MG, Means-Christensen A, **Bystritsky A**, Katon W, Sullivan G, Roy-Byrne PP. Quality of care for primary care patients with anxiety disorders, Am J Psychiatry, Dec;161(12):2230-7, 2004.
74. **Bystritsky A**, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. Apr;65(4):565-8, 2004.
75. Stein MB, Sherbourne CD, Craske MG, Means-Christensen A, **Bystritsky A**, Katon W, Sullivan G, Roy-Byrne PP. Quality of care for primary care patients with anxiety disorders, Am J Psychiatry, Dec;161(12):2230-7, 2004.

76. **Bystritsky A.** Anxiety Disorders: Diagnosis, Dimensions, and Process, Primary Psychiatry, Nov;12(11):33-34, 2005.
77. Feusner J, Cameron M, **Bystritsky A.** Pharmacotherapy and Psychotherapy for Panic Disorder, Primary Psychiatry, Nov;12:49-55, 2005.
78. Stein MB, Pollack MH, **Bystritsky A**, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial, Psychopharmacology (Berl), Jan;177(3):280-8, 2005.
79. Bogan AM, Koran LM, Chuong HW, Vapnik T, **Bystritsky A.** Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study, J Clin Psychiatry, Jan;66(1):73-9, 2005.
80. Roy-Byrne PP, Craske MG, Stein MB, Sullivan G, **Bystritsky A**, Katon W, Golinelli D, Sherbourne CD. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder, Arch Gen Psychiatry, Mar;62(3):290-8, 2005.
81. Roy-Byrne PP, **Bystritsky A**, Russo J, Craske MG, Sherbourne CD, Stein MB. Use of herbal medicine in primary care patients with mood and anxiety disorders, Psychosomatics, Mar-Apr;46(2):117-22, 2005.
82. Wagner AW, **Bystritsky A**, Russo JE, Craske MG, Sherbourne CD, Stein MB, Roy-Byrne PP. Beliefs about psychotropic medication and psychotherapy among primary care patients with anxiety disorders, Depress Anxiety, 21(3):99-105, 2005.
83. Craske MG, Edlund MJ, Sullivan G, Roy-Byrne P, Sherbourne C, **Bystritsky A**, Stein MB. Perceived unmet need for mental health treatment and barriers to care among patients with panic disorder, Psychiatr Serv, Aug;56(8):988-94, 2005.
84. **Bystritsky A**, Wagner AW, Russo JE, Stein MB, Sherbourne CD, Craske MG, Roy-Byrne PP. Assessment of beliefs about psychotropic medication and psychotherapy: development of a measure for patients with anxiety disorders, Gen Hosp Psychiatry, Sep-Oct;27(5):313-8, 2005.
85. **Bystritsky A.** Diagnosis and Treatment of Anxiety (in Russian), Bridging Eastern and Western Psychiatry, III(2):1-11, 2005.
86. Kobak KA, Taylor LV, **Bystritsky A**, Kohlenberg CJ, Greist JH, Tucker P, Warner G, Futterer R, Vapnik T. St John's Wort versus placebo in obsessive-compulsive disorder: results from a double-blind study, Int Clin Psychopharmacol, Nov;20(6):299-304, 2005.
87. Craske MG, Golinelli D, Stein MB, Roy-Byrne P, **Bystritsky A**, Sherbourne C. Does the addition of cognitive behavioral therapy improve panic disorder treatment outcome relative to medication alone in the primary-care setting?, Psychol Med, Nov;35(11):1645-54, 2005.

88. Stein MB, Roy-Byrne PP, Craske MG, **Bystritsky A**, Sullivan G, Pyne JM, Katon W, Sherbourne CD. Functional impact and health utility of anxiety disorders in primary care outpatients, Med Care, Dec;43(12):1164-70, 2005.
89. **Bystritsky A**. Anxiety Disorders: Diagnosis, Dimensions and Process, Primary Psychiatry, Nov; 12 (11) 33-34, 2005.
90. Feusner J, Cameron M, **Bystritsky A**. Pharmacotherapy and Psychotherapy for Panic Disorder, Primary Psychiatry, Nov; 12 (11) 33-34, 2005.
91. **Bystritsky A**, Wagner AW, Russo JE, Stein MB, Sherbourne CD, Craske MG, Roy-Byrne PP. Assessment of beliefs about psychotropic medication and psychotherapy: development of a measure for patients with anxiety disorders, Gen Hosp Psychiatry, Sep-Oct;27(5):313-8, 2005.
92. Bell S, Shipman M, **Bystritsky A**, Haifley T. Fluoxetine treatment and testosterone levels, Ann Clin Psychiatry, Jan-Mar;18(1):19-22, 2006.
93. **Bystritsky A**. Treatment-resistant anxiety disorders, Mol Psychiatry, Sep;11(9):805-14, 2006.
94. **Bystritsky A**, Zvartau EE, Neznanov NG. Differential Diagnosis of Panic Disorder (in Russian), Psychiatry and Medical Psychology, 3:16-20, 2006.
95. Craske MG, Roy-Byrne P, Stein MB, Sullivan G, Hazlett-Stevens H, **Bystritsky A**, Sherbourne C. CBT intensity and outcome for panic disorder in a primary care setting, Behav Ther, Jun;37(2):112-9, 2006.
96. Sullivan G, Craske MG, Sherbourne C, Edlund MJ, Rose RD, Golinelli D, Chavira DA, **Bystritsky A**, Stein MB, Roy-Byrne PP. Design of the Coordinated Anxiety Learning and Management (CALM) study: innovations in collaborative care for anxiety disorders, Gen Hosp Psychiatry, Sep-Oct;29(5):379-387, 2007.
97. Feusner JD, Townsend J, **Bystritsky A**, Bookheimer S. Visual Information Processing of Faces in Body Dysmorphic Disorder, Arch Gen Psychiatry. 2007 Dec;64(12):1417-25.

RESEARCH PAPERS (peer reviewed) – In Press

1. **Bystritsky A**, Kerwin L, Feusner J. A pilot study of the herbal supplement *Rhodiola rosea* in the treatment of Generalized Anxiety Disorder (GAD), *Alternative and Complementary Medicine*, in press, 2008
2. **Bystritsky A**, Kerwin L, Feusner JD, Vapnik T. A pilot controlled trial of bupropion XL vs. escitalopram in generalized anxiety disorder (GAD), *Psychopharmacology Bulletin*, in press: 2008.
3. **Bystritsky A**, Kerwin L, Feusner JD. A pilot study of cranial electrotherapy stimulation for generalized anxiety disorder, *Journal of Clinical Psychiatry*, in press: 2008.
4. Feusner JD, **Bystritsky A**. UCLA Anxiety Disorders Clinic: Training Psychiatric Residents in Cognitive-Behavioral Therapy and Pharmacotherapy in a Specialty Population, Preliminary Results, *Depression and Anxiety*, in press: 2008.
5. **Bystritsky A**, Kaplan J, Feusner J, Wadekar M, Kerwin L, Burock M, Wu A, Iacoboni M. Preliminary study of fMRI guided rTMS in the treatment of GAD, *Journal of Clinical Psychiatry*, in press: 2008.
6. **Powers, M.B.**, Smits, J., Whitley, D., Bystritsky, A., & Telch, M. The Effect of Attributional Processes Concerning Medication Taking on Return of Fear. *Journal of Consulting and Clinical Psychology*, in press 2008

RESEARCH PAPERS (peer reviewed) – Submitted

1. Story TJ, Craske ME, Connor BT, **Bystritsky A**, Roy-Byrne PP, Stein M, Sherbourne C. Beliefs about psychotherapy: scale construction, *Psychiatry Research*, *Submitted*.
2. Feusner JD, **Bystritsky A**, Helleman, G, Bookheimer S. Impaired Implicit Processing of Faces with Emotional Expressions in Body Dysmorphic Disorder, *Submitted*.
3. **Bystritsky A**, Kerwin L, Feusner JD, Vapnik T. Preferential efficacy of bupropion XL over escitalopram in the treatment of generalized anxiety disorder (GAD), *Submitted*.
4. **Bystritsky A**, Natoli J, Klap R, Wells KB, Young A. Prevalence of Psychiatric Comorbidities Among Subjects with Clinical and Subthreshold Panic Disorder, *Submitted*.

RESEARCH PAPERS (non-peer reviewed)

1. **Bystritsky A.** Imipramine in panic/agoraphobia: Finding the dose, Clinical Psychiatry News, 22:5:2 & 21, 1994.
2. **Bystritsky A.** Pharmacological treatment of social phobia, Newsletter, Southern California Psychiatric Association, 1996.
3. Feusner J, **Bystritsky A.** Management of Treatment Resistant OCD, Psychiatric Times, XXII (8):18-22, 2005.

BOOKS/BOOK CHAPTERS

1. **Bystritsky A**, Martynichkin AV. The study of the tranquilizing action of lorazepam and chlordiazepoxide on the models of concurrent interaction, In: Valdman AV (Ed.). Psychopharmacology of Emotional Stress and Zoosocial Interactions, Medical Literature, Leningrad, 1975.
2. Katkova EB, **Bystritsky AS**, Martynichkin AV. The comparative effect of sidnocarbe and amphetamine on the emotional behavior act, In: Valdman AV (Ed.). Psychopharmacology of Emotional Stress and Zoosocial Interactions, Medical Literature, Leningrad, 1975.
3. Goldstein M, Lew JY, **Bystritsky A**, Liberman A, Engel J, Lilijequist S. Multiple dopamine receptors: Interaction with alpha-2 receptors, In: Agnoli A, Crepaldi G, Spano PF, Trabucchi M (Eds.). Aging Brain and Ergot Alkaloids, 241-248. Raven Press, New York, 1983.
4. Pasnau RO, **Bystritsky A.** The anxiety disorders: A review, In: Kales A, Pierce C, Greenblatt M (Eds.). The Mosaic of Contemporary Psychiatry in Perspective, 1992.
5. Pasnau RO, **Bystritsky A.** Anxiety and depression, coexistence and comorbidity, In: Den Boer I (Ed.). Handbook of Anxiety and Depression, Elsevier, 1995.
6. **Bystritsky A**, Williams K., Treatment of Panic Disorder, In: Rakel and Bope (Eds.), Conn's Current Therapy Guide, Elsevier, 2005, 2006, 2007 editions.
7. **Bystritsky A.** Neuropharmacological and Therapeutic Aspects of Panic Disorders, St. Petersburg, 2006.
8. Rapgay L, **Bystritsky A.** Longevity & Optimal Health: Integrating Eastern and Western Perspectives. Forthcoming Volume, February 2008, edited by W. C. Bushell, MIT; & Eiuern L Olivo, Columbia University. (in press)

LETTERS TO THE EDITOR

1. **Bystritsky A.** A case report of high dose klonopin dependence, Clinical Psychiatry, 1993.
2. **Bystritsky A**, Vapnik T. Dismorphophobia group treatment, Letter, Peer Reviewed, Depress Anxiety, 5:39-40, 1997.

REVIEWS

None

EDITORIALS

None

PAPERS IN PREPARATION (research completed)

28 additional publications are being prepared.

ABSTRACTS

1. Petriaevskaya NV, Nesterovich NA, Martynichkin AV, **Bystritsky A.** The Pharmacological regulation of acute and chronic stress in an experiment, In: Theses of the 4th All-Union Congress of Pharmacology, Leningrad, 1976.
2. **Bystritsky A**, Ware JE, Linn LS. Development of a four dimensional anxiety scale, Abstracts of National Meeting of R.W.J. Clinical Scholars, Tampa, FL, 1988.
3. Shekim WO, **Bystritsky A**, Hess EB. Anxiety disorders and ADHD, New Research Abstracts, American Psychiatric Association, NR328, 1989.
4. Levine S, **Bystritsky A.** The treatment of major depression, new onset, in patients with HIV Positive serology, without active disease, with fluoxetine, Abstract C.584, Fifth International Conference on AIDS, International Development Research Center, page 655, 1989.
5. Levine SH, Anderson D, **Bystritsky A.** The treatment and evaluation of depression in patients infected with HIV, Abstract 54, presented at APA, paper session (peer reviewed), 87-88, New York, 1990.
6. **Bystritsky A**, Fogelson DL, Doctor R. Differences between patients with different orientation, Abstract 98, Presented at APA, paper session (peer reviewed), 103, New York, 1990.

7. Targ E, Karasic D, **Bystritsky A**, Diefenbach P, Anderson D, Fawzy F. Structured group therapy and fluoxetine as treatment for mood disorder in HIV-seropositive individuals, Abstract, International Conference on AIDS, Amsterdam, 1992.
8. Fredrick N, Martin K, Baxter L, **Bystritsky A**. A day hospital program for OCD, Abstract, Anxiety Disorders Association Conference, Charleston, SC, 1993.
9. **Bystritsky A**, Rosen RM, Faull K, Murphy KJ. Double-blind pilot trial of desipramine vs. fluoxetine in panic patients, Abstract, ADAA Meeting, Santa Monica, 1994.
10. Gorbis E, Munford PR, **Bystritsky A**. Abuse as a factor in expression and treatment of OCD, Abstract, ADAA Meeting, Santa Monica, 1994.
11. Lipovetsky V, **Bystritsky A**. Prevalence of anxiety disorders in a sample of immigrants from Russia, Abstract, ADAA Meeting, Santa Monica, 1994.
12. **Bystritsky A**, Craske MG, Shapiro D. Ambulatory blood pressure monitoring in panic patients, Abstract, ADAA Meeting, Santa Monica, 1994.
13. Vapnik T, Martin K, **Bystritsky A**. OCD and the family perspective, Abstract, ADAA Meeting, Santa Monica, 1994.
14. Small G, Schneider LS, Holman S, **Bystritsky A**. Site variability in a geriatric depression trial, Abstract, APA Meeting, Philadelphia, 1994.
15. Small G, Schneider LS, Holman S, **Bystritsky A**. Estrogen plus fluoxetine for geriatric depression, Abstract, APA Meeting, Philadelphia, 1994.
16. Craske MG, Maidenberg E, **Bystritsky A**. Brief cognitive behavior treatment of panic, Abstract, Symposium at AABT, Treatment of Panic with Agoraphobia. San Diego, 1994.
17. Kronig MH, Apter J, Asnis G, **Bystritsky A**, et al. A multicenter trial of sertraline for obsessive compulsive disorder, Abstract, American College of Neuropsychopharmacology, San Juan, 1995.
18. **Bystritsky A**, Maidenberg E, Craske MG, Vapnik T, Schapiro D. Autonomic reactivity of panic patients during CO₂ inhalation procedure, Abstract and Poster presentation, Annual Meeting, American Psychiatric Association, New York, 1996.
19. **Bystritsky A**, Maidenberg E, Craske MG, Vapnik T, Schapiro D. Autonomic reactivity of panic patients during psychophysiological assessment. Abstract and Oral presentation, Symposium on Psychophysiology of Panic Disorder, Abstract, Annual Meeting, American Psychiatric Association, San Diego, 1997.

20. **Bystritsky A**, Vapnik T, Leuchter A. Computerized EEG Abnormalities in non-medicated panic patients, Abstract and Poster, presented at NCDEU Meeting Boca Raton, FL, 1997.
21. **Bystritsky A**, Saxena S, Maidment K, Vapnik T, Tarlow G, Rosen R. Quality of life changes in treatment-resistant OCD, Abstract and Poster presentation, ACNP Meeting, Waikoloa Village, HI, 1997.
22. **Bystritsky A**, Rosen R, Suri R, Vapnik T. Pilot open-label study of nefazodone in panic disorder, Abstract and Poster presentation, ACNP Meeting, Waikoloa Village, HI, 1997.
23. **Bystritsky A**, Craske MG, Maidenberg E, Vapnik T, Schapiro D. Breathing configuration of panic patients during a CO₂ inhalation procedure, Abstract and Poster presented at NCDEU Meeting, Boca Raton, FL, 1998.
24. **Bystritsky A**, Liberman RP, Hwang S, Saxena S, Maindment K, Vapnik T. Comparison of the functional status of patients with severe obsessive-compulsive disorder vs. schizophrenia pre-and post-treatment, Abstract, NCDEU Meeting, Boca Raton, FL, 1999.
25. Ackerman DL, Greenland S, **Bystritsky A**, Small G. Side effects and time of response in placebo-controlled trial of fluoxetine in geriatric depression, Abstract, NCDEU Meeting, Boca Raton, FL, 1999.
26. Ackerman DL, **Bystritsky A**. Utilization and cost comparison of inpatient antidepressant drugs, Abstract, NCDEU Meeting, Boca Raton, FL, 1999.
27. **Bystritsky A**, Maindment K, Vapnik T, Tarlow G. Management clients with treatment resistant OCD, Abstract and Symposium presented at the Anxiety Disorders Association of America Annual Meeting, San Diego, 1999.
28. **Bystritsky A**, Craske MG, Maidenberg E, Vapnik T, Schapiro D. Cardiovascular and respiratory changes in panic patients in the light of current biological theories of Panic, Abstract and Oral Presentation, presented at the Anxiety Disorders Association of America Annual Meeting, San Diego, 1999.
29. **Bystritsky A**, Craske MG, Sandbrand DC. Preliminary analysis of the neuropsychological effects of visual imagery in panic disorder patients: An fMRI study, Abstract and Oral Presentation, presented at the Anxiety Disorders Association of America Annual Meeting, San Diego, 1999.
30. **Bystritsky A**, Bystritsky M. Russian language assessment of mental illness, Symposium Presentation and Abstract, Annual Meeting of American Psychiatric Association, Washington DC, 1999.

31. **Bystritsky A**, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of SRI response in refractory OCD using adjunct olanzapine: A placebo-controlled study, Abstract and Poster, ACNP, San Juan, 2000.
32. **Bystritsky A**, Pontillo D, Powers M, Sabb FW, Craske MG, Bookheimer SY. FMRI changes in panic patients during imagery exposure, Abstract and Poster, ACNP, San Juan, 2000.
33. **Bystritsky A**, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of SRI response in refractory OCD using adjunct olanzapine: A placebo-controlled study, Abstract, Eli Lilly Investigators Conference, Dallas, 2001.
34. **Bystritsky A**, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of SRI response in refractory OCD using adjunct olanzapine: A placebo-controlled study, Abstract, New Clinical Drug Evaluation Unit Program, Boca Raton, FL, 2001.
35. **Bystritsky A**, Pontillo D, Powers M, Sabb FW, Craske MG, Bookheimer SY. FMRI changes in panic patients during imagery exposure. Presentation and Abstract, Psychiatric Research Society, Park City, UT, 2001.
36. Roy-Byrne P, Russo J, Pollack M, Steward R, **Bystritsky A**, Bell J, Rosenbaum J, Corrigan MH, Stolk J, Rush AJ, Ballenger J. Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder, Abstract and Poster, ACNP, San Juan, 2002.
37. Roy-Byrne PP, Sherbourne CD, Craske MG, Stein MB, Katon WJ, Sullivan G, Means A, **Bystritsky A**. CBT and Medication for Primary Care Panic Disorder: Sustained Superiority to Usual Care, Abstract and Poster, ACNP, San Juan, 2002.
38. **Bystritsky, A**. Current Treatments of OCD. Abstract and Poster Proceeding of the Bekhterev Institute, St. Petersburg, Russia, July 2002.
39. **Bystritsky, A**. OCD Management in Partial Program, Abstract and Poster, 6th IOCDC Meeting, Lanzarote, Spain, November 2003.
40. **Bystritsky, A**. Anxiety as Residual Symptoms of Depression, APA Symposia and Abstract., APA Annual Meeting, New York, May 2004.
41. Feusner, JD, **Bystritsky A**. Effect Size of UCLA 4-D Anxiety-Depression Scale as Compared to Other Anxiety Scales, Abstract and Poster, Anxiety Disorder Association Of America, Abstract and Poster, Florida, March 2004.
42. **Bystritsky A**, Natoli J, Klap R, Wells KB, Young A. Prevalence of Psychiatric Comorbidities Among Subjects with Clinical and Subthreshold Panic Disorder. Abstract and Poster, 1-67. New Clinical Drug Evaluation Unit Program, Boca Raton, FL, May 2005.

43. **Bystritsky A**, Natoli J, Klap R, Wells KB, Young A. Prevalence of Psychiatric Comorbidities Among Subjects with Clinical and Subthreshold Panic Disorder. Abstract and Poster, International Conference: Bridging Eastern and Western Psychiatry, Moscow, June 2005.
44. Prenoveau JM, Craske M, Roy-Byrne PP, Sherbourne CD, Stein MB, **Bystritsky A**. Predictors of Willingness to Consider Medication and Psychological Treatment for Panic Disorder in Primary Care. Abstract and Poster, Association of Behavior and Cognitive Therapies. Washington D.C., November, 2005.
45. **Bystritsky A**, Kerwin L, Vapnik T. A Pilot Controlled Trial of Bupropion vs.Es-Citalopram in GAD, Abstract and Poster, Psychiatric Congress, Las Vegas, November, 2005.
46. **Bystritsky A**, Kerwin L, Vapnik T. A Pilot Controlled Trial of Bupropion vs.Es-Citalopram in GAD, Abstract and Poster, ACNP, Hawaii, December, 2005.
47. **Bystritsky A**, Kerwin L, Vapnik T. A Pilot Controlled Trial of Bupropion vs.Es-Citalopram in GAD, Abstract and Poster, APA, Toronto, May, 2006.
48. **Bystritsky A**, Koback K., Vapnik T. A Double Blind, Placebo Controlled Trial of St. John's Wart in OCD, Paper and Abstract, Complimentary and Alternative Treatments Conference, Edmonton-Alberta, Canada, May 2006.
49. **Bystritsky A**, Kerwin L, Vapnik T. A Pilot Controlled Trial of Bupropion vs.Es-Citalopram in GAD, Abstract and Poster, NCDEU, Boca Raton, Florida, June, 2006.
50. **Bystritsky A**, Kerwin L, Vapnik T. A Pilot Controlled Trial of Bupropion vs.Es-Citalopram in GAD, Abstract and Poster, Institute of Psychiatry, New York, October, 2006.
51. Feusner JD, **Bystritsky A**, Townsend J, Bookheimer S. Visual information processing of faces in body dysmorphic disorder. Abstract and Poster, The American College of Neuropsychopharmacology Annual Meeting, 2006.
52. Powers MB, Smits J, Whitley D, **Bystritsky A**, Telch M. Attributional processes concerning medication taking following exposure-based treatment and their subsequent effects on return of fear at follow-up. Anxiety Disorders Association of America, St. Louis, Missouri. Abstract, March, 2007.
53. **Bystritsky A**, Kerwin L, Feusner JD. A pilot study of *Rhodiola rosea* (Rhodax®) for generalized anxiety disorder (GAD). Abstract, American Psychiatric Association annual meeting, 2007.
54. Feusner JD, Townsend J, **Bystritsky A**, McKinley M, Bookheimer S. Magnetic resonance volumetric analysis of brain regions in body dysmorphic disorder: preliminary results. Abstract, American College of Neuropsychopharmacology Annual Meeting, Boca Raton, FL, 2007.

55. **Bystritsky A**, Kaplan J, Feusner JD, Wadekar M, Burock M, Iacoboni M. A preliminary study of fMRI-guided rTMS in the treatment of Generalized Anxiety Disorder. Abstract, American College of Neuropsychopharmacology Annual Meeting, Boca Raton, FL, 2007.
56. Powers MB, Smits J, Whitley D, **Bystritsky A**, Telch M. Attribution processes concerning medication taking following exposure-based treatment and their subsequent effects on return of fear at follow-up. Abstract and Presentation, World Congress of Behavioural and Cognitive Therapies, Barcelona, Spain, July, 2007.
57. Powers MB, Smits JA, Whitley D, **Bystritsky A**, Telch M. Attributional processes concerning medication taking and their subsequent effects on fear reduction during exposure-based treatment: A work in progress. Poster and Abstract, the Association for the Advancement of Behavior Therapy, New Orleans, Louisiana, 2007.

MANUALS/SCALES

1. **Bystritsky A**, Ware JE, Linn LS. Four Dimensional Anxiety Scale (FDAS) Manual, University of California, Los Angeles, 1988.
2. **Bystritsky A**, Selivra E, Bystirtsky M. M.I.N.I Diagnostic Interview, Russian Translation, 1998, 2004.
3. Craske MG, Roy-Byrne PP, Stein MB, **Bystritsky A**. Collaborative Care Manual For Treatment of Panic In Primary Care, 2000, 2004.

Patents:

USPTO 11/895,687 Methods for Modifying Electrical Currents in Neuronal Circuits